PhRMA Statement on President Biden’s Address to Joint Session of Congress
WASHINGTON, D.C. (April 28, 2021) – Pharmaceutical Research and Manufacturers of America president and CEO Stephen J. Ubl issued the following statement today after President Biden delivered an address to a joint session of Congress:
“President Biden and his team are to be commended for their leadership fighting the COVID-19 pandemic. Biopharmaceutical research companies are working around the clock, in close collaboration with our government partners, to deliver the scientific solutions we need to end the pandemic throughout the world and get Americans back to work. We also stand ready to work with policymakers to help address other tough challenges facing our country, including being better prepared for future pandemics and making medicines more affordable. However, giving the government the power to arbitrarily determine the price of medicines is not the right approach, which is why we’ve offered a better way to lower medicine costs for patients while at the same time protecting access to current and future treatments and cures.”
To learn more about our solutions for lowering patients’ drug costs, visit phrma.org/betterway.
The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier and more productive lives. Since 2000, PhRMA member companies have invested nearly $1 trillion in the search for new treatments and cures, including an estimated $83 billion in 2019 alone